38 slides from Predict S.p.a. Class B's investor presentation, October 2026
Slide 1: Predict S.p.A. Investor Presentation
PREDICT S.p.A. Investor Presentation October 2026
Slide 2: At a Glance
AT A GLANCE Hi-Tech solutions for advanced diagnostics ~20years 33 Predict S.p.A., based in Bari, is an innovative SME active in the Highly of partnership med-tech sector, specializing in non-invasive in vivo diagnostics. qualified with GE €0.84mn employees* It markets medical imaging systems for sc
Slide 3: Milestones
MILESTONES DISTRIBUTION AGREEMENTS Shenzhen Spinq | Airs Medical EU | UVC Solutions | Caresmed ORDERS/CONTRACTS 2 Mistral Samplers+services (IRCCS Bari) | MQ Analyzer (DIF Bari) | 2 Mistral Samplers PoliBA | 3 2026 Robots Corporea Museum (NA) | LiberAUT Project | RTI Tender «AMiCa» | Fetal ultrasoun
Slide 4: Industry Business System and Business Model
INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes. UNIVERSITIES PATIENTS SUPPLIERS IRCCS CUSTOMERS AND CITIZENS HOSPI
Slide 5: Strategic Business Units
STRATEGIC BUSINESS UNITS The activities of Predict are divided into 4 Strategic Business Units: Traditional Innovative SBU Imaging People Support Mistral Digital Healthcare • Sale of medical imaging • Technical support for • Development, design & • Development and sale of equipment*, marketed in the
Slide 6: Products and Application Portfolio
PRODUCTS AND APPLICATION PORTFOLIO Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment. Traditional Innovative SBU Imaging People Support Mistral Digital Healthcare Mistral Sampler Optip Surgery Optip
Slide 7: Synergies Between the Different SBUs
SYNERGIES BETWEEN THE DIFFERENT SBUs Supply of integrated Tele- ultrasound solutions with OPTIP products connected via Streambox to GE HealthCare ultrasound machines Digital After-sales assistance provided by the People Support SBU for Healthcare products offered by the Digital Healthcare SBU After-
Slide 8: Value Chain and Business Process
VALUE CHAIN AND BUSINESS PROCESS Predict sells its products both through direct orders from private customers and through bids open to public and private entities. ORDERS FROM Pre-sales/product Offering Sales Post-sales PRIVATE CUSTOMERS marketing Imaging EDUCATION LAUNCH People Support RESEARCH ONB
Slide 9: Suppliers and Clients
SUPPLIERS AND CLIENTS SUPPLIERS CLIENTS ü Manufacturers of Imaging Equipment PUBLIC: ü university clinics ü Companies providing in vivo diagnostic Imaging ü IRCCS services ü Public Hospitals ü Universities ü Primary and ü Manufacturers of systems for gas chromatography Secondary Schools and mass spe
Slide 10: Research and Development
RESEARCH AND DEVELOPMENT • 2016-22: completed breath sample collection system (Mistral Sampler) and CE mark. In 4Q21-1H22 Mistral Lab breath analysis laboratory built and launched. In 3Q22 Process automation of the Lab's examination procedures • FY23: AI algorithms have been defined to perform autom
Slide 11: Patents and CE Trademarks
PATENTS AND CE TRADEMARKS 12/2025 Filing of Italian patent application for Optip Nuva 08/2017 09/2021 Filing of European patent application 12/2019 Patent granted in the USA, Filing of CE trademark no. 11,122,164 B2 08/2018 02/2020 03/2023 2026 Filing of international PCT patent Filing of CE tradema
Slide 12: Reference Markets and Drivers
REFERENCE MARKETS AND DRIVERS Predict operates in 3 market niches in the Healthcare sector, growing globally: 1 Imaging 2 Breath analysis 3 Digital Health Tech A t I n t e r n a t i o n a l l e v e l +5% $ bn +23% $ bn CAGR 2026-2033 +17% $ bn CAGR 2026-2033 CAGR 2023-2030 1.830 65 9 46 3 347 2026 2
Slide 13: Management Team & Key People
MANAGEMENT TEAM & KEY PEOPLE Isabella Cafagna Loredana Amoruso Angelo Gigante Vice President and CEO CEO Founder, President, CEO Director SBU Mistral, SBU Digital Healthcare Tender and Legal Affairs Manager 20+ years of experience 10+ years of experience 10+ years of experience 2008: founds Predict
Slide 14: Shareholding and Governance
SHAREHOLDING AND GOVERNANCE SHAREHOLDING GOVERNANCE Board of Directors** Angelo Aurelio Paola Angelo Aurelio Gigante Gigante Sciancalepore President and CEO Isabella Cafagna Loredana Amoruso 51% 49% Vice President, Executive Director Executive Director Rocco Dichio Valeria Stucci Treasury Other Dire
Slide 15: ESG
ESG G Certifications E S Scope 1 Emissions Production Bonuses Gender Equality Committee Implementation of a PDR linked 40% Male Employees 65 tCO₂e tot. | 2.4 tCO₂e per FTE to the achievement of EBITDA- 60% Female Employees related objectives Scope 2 Emissions ESG Committee 14.1 tCO₂e tot. | 0.52 tCO
Slide 16: Growth Strategies
GROWTH STRATEGIES Development of § R&D, partnerships with clinical research centers and university TTOs § Hiring of new professional roles, strengthening of commercial functions, innovative SBUs and product development with a focus on § Roll-out of a network of Mistral Labs in Italy Mistral § Develo
Slide 17: Financial Highlights 1H26
FINANCIAL HIGHLIGHTS 1H26 Revenue / VoP (€mn) EBITDA (€mn) Net Result (€mn) NFI / NFI Adj.* (€mn) Equity (€mn) 17 *Adjustments attributable to receivables accrued under the regional PIA project, unchanged vs. 31/12/2025
Slide 18: 1H26 vs 1H25 Income Statement
1H26 vs 1H25 INCOME STATEMENT Reclassified Income Statement (Euro/000) 30.06.2026 %(*) 30.06.2025 %(*) Var. % Sales Revenues 4,014 100.0% 2,400 100.0% 67.3% Increases in fixed assets for internal work 311 7.7% - 0.0% n/a Other revenues and income 331 8.2% 247 10.3% 34.0% Value of Production 4,656 11
Slide 19: 1H26 vs 1H25 SBU Income Statement: Imaging
1H26 vs 1H25 SBU INCOME STATEMENT Imaging SBU Imaging Income Statement 30.06.2026 %(*) 30.06.2025 %(*) Var. % (Data in Euro/000) 1H26-1H25 Sales Revenues 3,149 100.0% 1,789 100.0% 76.0% Increases in fixed assets – 0.0% – 0.0% n/a Other revenues and income 60 1.9% 40 2,3% 50.0% Value of Production 3,
Slide 20: 1H26 vs 1H25 SBU Income Statement: People Support
1H26 vs 1H25 SBU INCOME STATEMENT People Support SBU People Support Income Statement 30.06.2026 %(*) 30.06.2025 %(*) Var. % (Data in Euro/000) 1H26-1H25 Sales Revenues 655 100.0% 502 100.0% 30.5% Increases in fixed assets – 0.0% – 0.0% n/a Other revenues and income 15 2.2% 12 2.3% 25.0% Value of Pro
Slide 21: 1H26 vs 1H25 SBU Income Statement: Mistral
1H26 vs 1H25 SBU INCOME STATEMENT Mistral SBU Mistral Income Statement 30.06.2026 %(*) 30.06.2025 %(*) Var. % (Data in Euro/000) 1H26-1H25 Sales Revenues 13 100.0% 19 100.0% -31.6% Increases in fixed assets 193 n/a – 0.0% n/a Other revenues and income 73 n/a 192 n/a -62.0% Value of Production 278 n/
Slide 22: 1H26 vs 1H25 SBU Income Statement: Digital Healthcare
1H26 vs 1H25 SBU INCOME STATEMENT Digital Healthcare SBU Digital Healthcare Income Statement 30.06.2026 %(*) 30.06.2025 %(*) Var. % (Data in Euro/000) 1H26-1H25 Sales Revenues 198 100.0% 90 100.0% >100.0% Increases in fixed assets 118 59.6% – 0.0% n/a Other revenues and income 184 93.0% 3 3.2% >100.
Slide 23: 1H26 vs FY25 Balance Sheet
1H26 vs FY25 BALANCE SHEET Riclassified Balance Sheet (Euro/000) 30.06.2026 %(*) 31.12.2025 %(*) Var. %1H26-FY25 Intangible fixed assets 1,128 32.9% 1,052 41.5% 7.2% Tangible fixed assets 465 13.6% 534 21.1% -12.9% Financial fixed assets 711 20.8% 702 27.7% 1.3% Net fixed assets ** 2,304 67.2% 2,289
Slide 24: Investment Highlights
INVESTMENT HIGHLIGHTS High-growth markets in Healthcare Strong demand for diagnostic technologies, leading to efficient offerings at lower costs "Turnkey" solutions High level of know-how and track record for breath analysis laboratories at University acquired by top management, Hospitals, IRCCS, an
Slide 25: Key Takeaways
KEY TAKEAWAYS 9M26 4Q26 &2027 Main achievements: In the next months Predict will focus on: SBU Imaging: SBU Imaging: • Consolidated client base in Puglia • Consolidating the collaboration with GE HealthCare • GE HealthCare agreement renewed (to January 2029) • Wider product range and possible extens
Slide 26: Predict on EGM
PREDICT ON EGM Market data IDENTIFIERS & STOCK Stock code PRE ISIN Ordinary Shares IT0005611071 N. Ordinary Shares 5,869,000 N. Multiple voting shares1 1,800,000 N. PAS2 60,000 IPO DATA Start date of trading 30/09/2024 Capital raised in IPO (pre greenshoe) € 1,519,500 Admission price € 1.00 IPO capi
Slide 27: Annex
LIFE CARE ANNEX
Slide 28: Financial Highlights FY25 vs FY24 & FY23
FINANCIAL HIGHLIGHTS FY25 vs FY24 & FY23 Revenue / VoP (€mn) EBITDA (€mn) Net Result (€mn) EBITDA% FY25: 10.3% (vs.12.2% FY24) NFI / NFI Adj. (€mn) Equity (€mn) 28
Slide 29: FY2025 vs FY2024 Income Statement
FY2025 vs FY2024 INCOME STATEMENT Reclassified Income Statement (Euro/000) 31.12.2025 %(*) 31.12.2024 %(*) Var. % FY25-FY24 Sales Revenues 7,595 100.0% 6,626 100.0% 14.6% Increases in fixed assets for internal work 581 7.7% - 0.0% n/a Other revenues and income 697 9.2% 712 10.7% -2.1% Value of Produ
Slide 30: FY2025 vs FY2024 SBU Income Statement: Imaging
FY2025 vs FY2024 SBU INCOME STATEMENT Imaging SBU Imaging Income Statement 31.12.2025 %(*) 31.12.2024 %(*) Var. % (Data in Euro/000) FY25-FY24 Sales Revenues 5,369 100.0% 5,173 100.0% 3,8% Increases in fixed assets for internal work – 0.0% - 0.0% n/a Other revenues and income 78 1.4% 23 0.4% >100,0%
Slide 31: FY2025 vs FY2024 SBU Income Statement: People Support
FY2025 vs FY2024 SBU INCOME STATEMENT People Support SBU People Support Income Statement 31.12.2025 %(*) 31.12.2024 %(*) Var. % (Data in Euro/000) FY25-FY24 Sales Revenues 1,151 100.0% 905 100.0% 27.2% Increases in fixed assets for internal work – 0.0% - 0.0% n/a Other revenues and income 17 1.5% 5
Slide 32: FY2025 vs FY2024 SBU Income Statement: Mistral
FY2025 vs FY2024 SBU INCOME STATEMENT Mistral SBU Mistral Income Statement 31.12.2025 %(*) 31.12.2024 %(*) Var. % (Data in Euro/000) FY25-FY24 Sales Revenues 242 100.0% 258 100.0% -6.2% Increases in fixed assets for internal work 360 148.8% - 0.0% n/a Other revenues and income 269 111.0% 421 163.5%
Slide 33: FY2025 vs FY2024 SBU Income Statement: Digital Healthcare
FY2025 vs FY2024 SBU INCOME STATEMENT Digital Healthcare SBU Digital Healthcare Income Statement 31.12.2025 %(*) 31.12.2024 %(*) Var. % (Data in Euro/000) FY25-FY24 Sales Revenues 833 100.0% 290 100.0% >100.0% Increases in fixed assets for internal work 221 26.6% - 0.0% n/a Other revenues and income
Slide 34: FY2025 vs FY2024 Balance Sheet
FY2025 vs FY2024 BALANCE SHEET Riclassified Balance Sheet (Euro/000) 31.12.2025 %(*) 31.12.2024 %(*) Var. %FY25-FY24 Intangible fixed assets 1,052 41.5% 790 39.4% 33.2% Tangible fixed assets 534 21.1% 563 28.1% -5.2% Financial fixed assets 702 27.7% 633 31.6% 10.9% Net fixed assets ** 2,289 90.3% 1,
Slide 35: Videos
VIDEOS SUPPLY OF TECHNOLOGIES FOR BREATH ANALYSIS CONSTRUCTION OF “TURNKEY” BREATH ANALYSIS LABORATORIES SUPPLY OF AR TECHNOLOGIES FOR TELE-ULTRASOUND SUPPLY OF AR TECHNOLOGIES FOR EDUCATION AND TRAINING SUPPLY OF HUMANOID ROBOTS FOR THE DEPARTMENT PREDICT SITE MISTRAL LAB 35
Slide 36: Marketing Mix
MARKETING MIX Imaging People Support Mistral Digital Healthcare - Personal selling Promotion - Industry trade fairs - Websites - Dissemination - Direct sale Placement - Public Tenders - Specialized sellers - Distribution policies|Price lists Pricing - Tailor made / Customized - Fixed+renewal / Value
Slide 37: Disclaimer
DISCLAIMER This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") a
Slide 38: Predict Investor Relations
PREDICT Bari Viale Adriatico, 4 c/o Fiera del Levante - Pad. 105 | +39 080 893 3754 Milano Piazza Gae Aulenti 1, Torre B | +39 02 9713 0325 Roma Via Marsala 29H | +39 06 4547 3124 predictcare.it INVESTOR RELATIONS MANAGER INVESTOR RELATIONS ADVISOR Angelo Ceci, CFO & IRM - Predict Chiara Cardelli, S